CN115449009B - Cholesterol molecularly imprinted polymer and preparation method and application thereof - Google Patents
Cholesterol molecularly imprinted polymer and preparation method and application thereof Download PDFInfo
- Publication number
- CN115449009B CN115449009B CN202211210223.1A CN202211210223A CN115449009B CN 115449009 B CN115449009 B CN 115449009B CN 202211210223 A CN202211210223 A CN 202211210223A CN 115449009 B CN115449009 B CN 115449009B
- Authority
- CN
- China
- Prior art keywords
- cholesterol
- molecularly imprinted
- imprinted polymer
- template molecule
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 246
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 122
- 229920000344 molecularly imprinted polymer Polymers 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000178 monomer Substances 0.000 claims abstract description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 13
- 230000001603 reducing effect Effects 0.000 claims abstract description 12
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000001179 sorption measurement Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 9
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 claims description 8
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 239000003999 initiator Substances 0.000 claims description 5
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 5
- 238000012673 precipitation polymerization Methods 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 229920001268 Cholestyramine Polymers 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002861 polymer material Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001278 effect on cholesterol Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- -1 fibrates Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/04—Acids; Metal salts or ammonium salts thereof
- C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/268—Polymers created by use of a template, e.g. molecularly imprinted polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/10—Esters
- C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
- C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/042—Elimination of an organic solid phase
- C08J2201/0422—Elimination of an organic solid phase containing oxygen atoms, e.g. saccharose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
In a first aspect, the present invention provides a cholesterol molecularly imprinted polymer, which is prepared by using cholesterol as a template molecule and has a cholesterol recognition site, so that the cholesterol molecularly imprinted polymer can capture and remove cholesterol in plasma with high selectivity. Preferably, the cholesterol molecularly imprinted polymer further comprises a functional monomer methacrylic acid and surface carrier silica. The invention also provides a preparation method of the cholesterol molecularly imprinted polymer, which comprises the following steps: s1, dissolving template molecule cholesterol in a reaction solvent, and adding a functional monomer methacrylic acid for prepolymerization to obtain a solution A; s2, adding a functional reagent into the solution A, and obtaining a product B after reaction; s3, eluting and drying the template molecules in the product B to obtain the cholesterol molecularly imprinted polymer. The invention further provides application of the cholesterol molecularly imprinted polymer in preparing products for adsorbing or reducing the cholesterol content in a human body, slowing down hyperlipidemia or reducing weight.
Description
Technical Field
The invention belongs to the technical field of high molecular polymer materials, and particularly relates to a cholesterol molecularly imprinted polymer and a preparation method and application thereof.
Background
Hyperlipidemia (hyperlipoidemia) refers to one or more lipids, including Total Cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-c) and low density lipoprotein cholesterol (LDL-c), which are important causes of atherosclerosis (atherosclerosis, as) and cardiovascular and cerebrovascular diseases due to elevated TC, TG and LDL-c or lower HDL-c symptoms in the plasma caused by abnormal fat metabolism or transport. Hypercholesterolemia, a pathological condition involved in a number of diseases related to inflammation and thrombosis, is one of the important pathogenic mechanisms, and can cause microvascular dysfunction, manifested by impaired arteriole endothelial-dependent vasodilation, capillary postvenal leukocyte and platelet aggregation, and oxidative stress damage in both arterioles and venules. The cholesterol in the body mainly comes from the synthesis of the liver, the absorption and secretion of intestinal tracts and other ways, and the excessive content of the cholesterol in the body can cause arteriosclerosis cardiovascular diseases and harm the health of human bodies.
In the prior art, the drugs for treating hypercholesterolemia mainly regulate and regulate cholesterol metabolism by inhibiting exogenous cholesterol absorption, reducing endogenous cholesterol synthesis, and promoting cholesterol transport and excretion. The current clinical drugs mainly comprise statins, fibrates, nicotinic acid and bile acid chelating agents. However, the above drugs often have some degree of side effects. For example, the first-choice drugs for clinical cholesterol lowering are HMG-CoA reductase inhibitors, i.e., statins such as lovastatin, simvastatin, etc., which act on the principle of reducing cholesterol synthesis by inhibiting the key enzyme 3-hydroxy-3-methylglutarate CoA reductase in the cholesterol synthesis pathway, which can significantly improve patient prognosis; but has the toxic and side effects of causing muscle pain, nerve disorder, digestive system diseases or liver function damage and the like, and partial patients are difficult to receive high-dose drug treatment.
For the prevention and treatment of obesity associated with high cholesterol, weight loss products currently on the market are mainly of the pancreatic lipase inhibitor and appetite suppressant type acting on the central nervous system. Pancreatic lipase inhibitors, such as orlistat, reduce weight by inhibiting pancreatic lipase activity and thus inhibiting the breakdown and absorption of fat in foods, but they may cause side effects such as fat-soluble vitamin deficiency and liver function impairment. Appetite suppressants can cause adverse effects on the nervous system, with safety risks in the brain center and cardiovascular system.
Disclosure of Invention
In view of the above problems, the first aspect of the present invention proposes a cholesterol molecularly imprinted polymer, which is prepared with cholesterol as a template molecule and has a cholesterol recognition site to adsorb cholesterol. The molecular imprinting polymer material using cholesterol as template molecule can capture and remove cholesterol in blood plasma with high selectivity.
Preferably, the cholesterol molecularly imprinted polymer further comprises a functional monomer methacrylic acid.
Preferably, the cholesterol molecularly imprinted polymer also comprises surface carrier silicon dioxide, which can form more adsorption sites on the surface of the cholesterol molecularly imprinted polymer, thereby improving adsorption efficiency and simultaneously having good biocompatibility.
The second aspect of the invention provides a preparation method of a cholesterol molecularly imprinted polymer, which comprises the following steps:
s1, dissolving template molecule cholesterol in a reaction solvent, and adding a functional monomer for prepolymerization to obtain a solution A;
s2, adding a functional reagent into the solution A, and obtaining a product B after reaction;
s3, eluting and drying the template molecules in the product B to obtain the cholesterol molecularly imprinted polymer.
Preferably, the reaction solvent comprises methanol, so that the cholesterol molecularly imprinted polymer has better adsorption effect.
Preferably, the functional monomer in S1 comprises methacrylic acid, the molar ratio of the template molecule cholesterol to the functional monomer methacrylic acid is 1:6, so that the cholesterol molecularly imprinted polymer has better adsorption effect.
Preferably, the functional agent in S2 comprises a crosslinker ethylene glycol dimethacrylate EDGMA, the molar ratio of template molecule cholesterol to crosslinker ethylene glycol dimethacrylate EDGMA being 1:10.
Preferably, the functional agent in S2 comprises initiator 2,2' -azobisisobutyronitrile AIBN, which is heated at high temperature to initiate precipitation polymerization to obtain product B.
Preferably, the method comprises the steps of,
S1, dissolving template molecule cholesterol in a reaction solvent, adding a functional monomer, and performing prepolymerization at a low temperature after ultrasonic dispersion;
s2, adding a cross-linking agent and a pore-forming agent after ultrasonic dispersion of the solution A, adding an initiator after deoxidization, and carrying out precipitation polymerization at a high temperature;
s3, eluting the template molecular cholesterol by using ethanol as an eluent through ultrasonic oscillation, and eluting the template molecular cholesterol by using pure water until a product B is neutral.
In a third aspect, the present invention provides the use of a cholesterol molecularly imprinted polymer according to the above or prepared by the above method for the preparation of a product for adsorbing or reducing cholesterol content, reducing hyperlipidemia or reducing weight in a human. The cholesterol molecularly imprinted polymer can be directly combined with cholesterol in blood plasma so as to discharge the cholesterol molecularly imprinted polymer from the body, compared with the existing product, the cholesterol reduction efficiency is improved, and the physical adsorption method has small toxic and side effects, so the cholesterol molecularly imprinted polymer is particularly suitable for the treatment of hypercholesterolemia patients and healthy weight-losing related products of obese people.
The invention provides a silica molecularly imprinted polymer material of cholesterol and a preparation method thereof, wherein cholesterol is selected as a template, and the molecularly imprinted polymer material capable of capturing cholesterol in human plasma is prepared by an atom transfer radical polymerization mode. Compared with the existing lipid-lowering drugs, the cholesterol molecularly imprinted polymer material prepared by the invention has high sensitivity and strong specific adsorption, can realize high-efficiency and rapid reduction of cholesterol in the body, has safety, and has excellent application prospect in treating hypercholesterolemia or related products with the efficacy of losing weight and lowering lipid.
Drawings
The accompanying drawings assist in a further understanding of the application. For convenience of description, only parts related to the related application are shown in the drawings.
FIG. 1 is a flow chart of a preparation method of a cholesterol molecularly imprinted polymer according to an embodiment of the invention;
FIG. 2 is a representation of the morphology of cholesterol molecularly imprinted polymers by transmission electron microscopy in another embodiment of the invention;
FIG. 3 is a morphological characterization of cholesterol molecularly imprinted polymer by scanning electron microscopy according to another embodiment of the invention;
FIG. 4 is an evaluation of biocompatibility and adsorption capacity of cholesterol molecularly imprinted polymers prepared in another embodiment of the invention.
Detailed Description
The application is described in further detail below with reference to the drawings and examples. The specific embodiments described herein are offered by way of illustration only, and not by way of limitation. Embodiments of the application and features of the embodiments may be combined with each other without conflict.
FIG. 1 is a flow chart of an embodiment of a process for preparing a cholesterol molecularly imprinted polymer, comprising the steps of:
s1, dissolving template molecule cholesterol in a reaction solvent, and adding a functional monomer for prepolymerization to obtain a solution A;
s2, adding a functional reagent into the solution A, and obtaining a product B after reaction;
s3, eluting and drying the template molecules in the product B to obtain the cholesterol molecularly imprinted polymer.
The Molecular Imprinting Technique (MIT) is a process of preparing a polymer having a specific selectivity for a specific molecule using the specific molecule as a template, i.e., preparing Molecularly Imprinted Polymers (MIPs) of the template molecule. The molecularly imprinted polymer has the characteristics of structural predictability, recognition specificity, application universality and the like. Generally, the molecularly imprinted polymer can be polymerized by a template molecule and a functional monomer in the presence of the template molecule. The template molecule is then removed, thereby obtaining a highly selective recognition site in the polymer structure that is complementary to the template molecule in size, shape and function of the three-dimensional imprinting cavity. According to the scheme, cholesterol is used as a template molecule to prepare the cholesterol molecularly imprinted polymer, the cholesterol molecularly imprinted polymer has high specific recognition and separation capacity on cholesterol, and can be specifically extracted from a complex system.
Fig. 2 is a representation of a cholesterol molecularly imprinted polymer by a transmission electron microscope in another embodiment, and fig. 3 is a representation of a cholesterol molecularly imprinted polymer by a scanning electron microscope in another embodiment. Referring to fig. 2 and 3, the morphological characterization of the cholesterol molecularly imprinted polymer shows that the polymer has uniform shape and size, the particle diameter is about 50nm, the surface is porous and uneven, and more imprinting sites are formed on the surface of the cholesterol molecularly imprinted polymer.
[ Embodiment one ]
In this example, the preparation of the cholesterol molecularly imprinted polymer comprises the steps of:
S1, dissolving 10 mu mol of template molecular cholesterol in 20mL of reaction solvent, adding functional monomer methacrylic acid, and prepolymerizing for 16h at 4 ℃ to obtain solution A;
S2, adding 100 mu mol of Ethylene Glycol Dimethacrylate (EGDMA) serving as a cross-linking agent and 40mL of Acetonitrile (ACN) serving as a pore-forming agent into the solution A, introducing nitrogen for 5min, adding 40mg of 2,2' -Azobisisobutyronitrile (AIBN) serving as an initiator, and placing the mixture in a water bath at 65 ℃ to react for 24h to obtain a product B;
s3, using ethanol as an eluent, removing template molecules by ultrasonic oscillation, eluting to be neutral by pure water, and freeze-drying to obtain the cholesterol molecularly imprinted polymer.
[ Example two ]
In this example, referring to the preparation method of example one, but selecting different reaction solvents to prepare cholesterol Molecularly Imprinted Polymers (MIPs), and correspondingly preparing non molecularly imprinted polymers (NIPs) by the same method but without adding template molecules, the adsorption result of the product on cholesterol is shown in the following table, and MIPs prepared in different reaction solvents all have adsorption effect on cholesterol, and methanol is the optimal reaction solvent.
TABLE 1 adsorption effect of MIPs prepared in different reaction solvents on cholesterol
[ Example III ]
In this example, referring to the preparation method of example one, cholesterol molecularly imprinted polymer MIPs were prepared with different molar ratios of template molecule cholesterol and functional monomer methacrylic acid, and non molecularly imprinted polymer MIPs were prepared with the same method correspondingly but without adding template molecule, after obtaining the product, adsorption was sufficiently performed at room temperature, and the adsorption results are shown in the following table. Therefore, the MIPs prepared by the template molecules and the functional monomers in different proportions have adsorption effect on cholesterol, and the optimal proportion is 1:6.
TABLE 2 adsorption Effect of MIPs prepared with different template molecules and functional monomers on cholesterol
[ Example IV ]
In this example, reference is made to the preparation method of example one, but cholesterol molecularly imprinted polymer MIPs are prepared with different materials as surface carriers, and correspondingly non molecularly imprinted polymer MIPs are prepared with the same method but without the addition of template molecules. Specifically, the process for preparing cholesterol molecularly imprinted polymer MIPs comprises adding 0.2g of silicon dioxide, 0.2g of ferroferric oxide or no surface carrier into solution a in step S2, performing ultrasonic dispersion for 20min, adding 100 mu mol of cross-linking agent Ethylene Glycol Dimethacrylate (EGDMA) and 40mL of pore-forming agent Acetonitrile (ACN), and continuing to react. The adsorption results of the obtained product to cholesterol are shown in the following table. It can be seen that polymers prepared with different surface carriers all have an adsorption effect on cholesterol, with silica being the optimal carrier.
TABLE 3 adsorption effect of MIPs prepared with different surface Carriers on cholesterol
[ Example five ]
In this example, cholesterol molecularly imprinted polymer MIPs were prepared by the preparation method of reference example one, and cholesterol adsorption was performed with cholestyramine as a comparison. Cholestyramine (cholestyramine) is one of bile acid sequestrants, which is one of the drugs for treating hypercholesterolemia, and is combined with cholesterol or bile acid in the body to be discharged from the body, thereby inhibiting the body from reabsorption of cholic acid; meanwhile, the cholestyramine can also combine with the surface protein of the liver cells in the organism, activate the liver cells and promote the liver cells to secrete a large amount of low-density lipoprotein receptor, thereby improving the absorption of the liver cells to the low-density lipoprotein in the blood; interfere with liver and intestine circulation, promote decomposition and excretion of cholesterol, and achieve the purposes of reducing the lipoprotein level of the organism and preventing and treating hyperlipidemia.
Specifically, taking 3 parts of blank plasma, respectively adding cholesterol standard substances to make the final concentration of the blank plasma be 1, 4 and 8mmol/L, respectively taking 5mL of sample solution, respectively adding 100mg of cholestyramine, and vibrating for 2 hours at room temperature to fully adsorb cholesterol; an additional 3 corresponding sample solutions were added to equal amounts of cholesterol molecularly imprinted polymer MIPs. 1mL of the adsorbed solution is taken for pretreatment, 4mL of acetonitrile is added, vortex is adopted to mix the solution uniformly, after standing for 10min, 200 mu L of the solution is taken for centrifugation at 12000rpm and 4 ℃ for 15min, the concentration of residual cholesterol is detected by high performance liquid phase, and the final adsorption result is shown in the following table, so that compared with cholestyramine, the cholesterol molecularly imprinted polymer MIPs prepared by the embodiment have better adsorption effect on cholesterol.
TABLE 4 adsorption Effect of cholesterol molecularly imprinted Polymer MIPs and cholestyramine on cholesterol
[ Example six ]
FIG. 4 is an evaluation of biocompatibility and adsorption capacity of cholesterol molecularly imprinted polymers prepared in one example. 3 healthy mice of the same week-old were taken, administered for 30 consecutive days (0.2 mg cholesterol molecularly imprinted polymer/g body weight), and weighed, and their body weight changes were observed. At the same time, 3 healthy mice of the same week-old were taken, administered for 30 consecutive days (0.2 mg cholestyramine/g body weight), and weighed to observe the change in body weight. Referring to fig. 4, after 30 days of continuous administration, mice survived, had good living status and slightly reduced body weight, and it can be seen that the cholesterol molecularly imprinted polymer prepared in this example has biological safety and the same, even better, body weight reducing effect as the hypolipidemic drug cholestyramine.
According to the invention, the cholesterol molecularly imprinted polymer is used as an adsorbent, and a cavity with a specific size and a functional group is formed in the adsorbent and used as a binding site of cholesterol, so that cholesterol in blood can be rapidly adsorbed, and then discharged out of the body. The cholesterol molecularly imprinted polymer has strong selectivity, good adsorption effect and small side effect, can be used as a pharmaceutical composition for preventing and treating diseases related to high cholesterol, and can also be used in weight-losing products or health-care products to help reduce weight.
While the present application has been particularly shown and described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the application as defined by the appended claims.
Claims (7)
1. A cholesterol molecularly imprinted polymer, wherein the cholesterol molecularly imprinted polymer is prepared by using cholesterol as a template molecule and has cholesterol recognition sites to adsorb cholesterol, wherein the preparation condition is that methanol is used as a reaction solvent, and the cholesterol molecularly imprinted polymer further comprises a functional monomer methacrylic acid and surface carrier silicon dioxide, wherein the surface carrier silicon dioxide forms a plurality of adsorption sites on the surface of the cholesterol molecularly imprinted polymer.
2. The preparation method of the cholesterol molecularly imprinted polymer is characterized by comprising the following steps:
s1, dissolving template molecule cholesterol in a reaction solvent methanol, and adding a functional monomer methacrylic acid for prepolymerization to obtain a solution A;
s2, adding a functional reagent into the solution A, and obtaining a product B after reaction;
S3, eluting and drying the template molecules in the product B to obtain a cholesterol molecularly imprinted polymer, wherein the cholesterol molecularly imprinted polymer comprises surface carrier silicon dioxide.
3. The method for preparing a cholesterol molecularly imprinted polymer according to claim 2, wherein the molar ratio of the template molecule cholesterol to the functional monomer methacrylic acid of S1 is 1:6.
4. The method for preparing a cholesterol molecularly imprinted polymer according to claim 2, wherein the functional reagent S2 comprises a cross-linking agent ethylene glycol dimethacrylate EDGMA, and the molar ratio of the template molecule cholesterol to the cross-linking agent ethylene glycol dimethacrylate EDGMA is 1:10.
5. The method for preparing a cholesterol molecularly imprinted polymer according to claim 2, wherein the functional reagent S2 comprises an initiator 2,2' -azobisisobutyronitrile AIBN, and the product B is obtained by heating to initiate precipitation polymerization.
6. The method for preparing the cholesterol molecularly imprinted polymer according to claim 2, wherein,
S1, dissolving template molecule cholesterol in a reaction solvent, adding a functional monomer, and performing prepolymerization at a low temperature after ultrasonic dispersion;
s2, specifically, adding a cross-linking agent and a pore-forming agent after ultrasonic dispersion of the solution A, adding an initiator after deoxidization, and carrying out precipitation polymerization at a high temperature;
s3, ultrasonic vibration is adopted to elute template molecule cholesterol by adopting ethanol as an eluent, and pure water is used for eluting until the product B is neutral.
7. Use of a cholesterol molecularly imprinted polymer according to claim 1 or prepared according to the method of any one of claims 2-6 for the preparation of a product for adsorbing or reducing cholesterol content, reducing hyperlipidemia or reducing weight in a human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211210223.1A CN115449009B (en) | 2022-09-30 | 2022-09-30 | Cholesterol molecularly imprinted polymer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211210223.1A CN115449009B (en) | 2022-09-30 | 2022-09-30 | Cholesterol molecularly imprinted polymer and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115449009A CN115449009A (en) | 2022-12-09 |
| CN115449009B true CN115449009B (en) | 2024-07-12 |
Family
ID=84308404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211210223.1A Active CN115449009B (en) | 2022-09-30 | 2022-09-30 | Cholesterol molecularly imprinted polymer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115449009B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802092D0 (en) * | 1998-06-12 | 1998-06-12 | Boerje Sellergren | Selective adsorbent |
| CN102353710B (en) * | 2011-07-08 | 2014-02-19 | 无锡市金坤生物工程有限公司 | Application of cholesterol molecule imprinted membrane sensing electrode in detecting blood cholesterol |
-
2022
- 2022-09-30 CN CN202211210223.1A patent/CN115449009B/en active Active
Non-Patent Citations (5)
| Title |
|---|
| "胆固醇分子印迹聚合微球的制备及其吸附性能";郭永学等;《过程工程学报》;第11卷(第2期);第318-323页 * |
| "胆固醇分子印迹聚合物的制备及其选择性吸附";张圣祖等;《化学通报》;第第74卷卷(第第2期期);第137-143页 * |
| "表面分子印迹材料和技术在分离分析中的应用进展";侯会卿等;《色谱》;第34卷(第12期);第1206-1214页 * |
| "表面分子印迹研究进展";丛姣姣等;《高分子通报》(第第5期期);第10-20页 * |
| 郭永学等."胆固醇分子印迹聚合微球的制备及其吸附性能".《过程工程学报》.2011,第11卷(第2期),第318-323页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115449009A (en) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6247740B2 (en) | Cross-linked polyvinylamine, polyallylamine and polyethyleneimine for use as bile acid scavengers | |
| JP2004528332A (en) | Method of treating gout and binding uric acid | |
| JPH06157671A (en) | Crosslinked nitrogen-containing vinyl copolymer, its production, and its use | |
| JP2001521902A (en) | Use of aliphatic polyamines to reduce oxalate | |
| KR102441934B1 (en) | Porous carbon particles for use in the treatment or prevention of liver disease | |
| JP2010090172A (en) | Method for lowering serum glucose | |
| EP2552459B1 (en) | Method of treating inflammation | |
| US6036948A (en) | Polyaspartamide derivatives as adsordents for bile acids, polyaspartamide derivatives loaded with bile acids and process for their preparation and their use as pharmaceuticals | |
| Odabaşı et al. | Cholesterol imprinted composite membranes for selective cholesterol recognition from intestinal mimicking solution | |
| JP2023033400A (en) | Poloxamer composition free of long circulating material and methods for production and uses thereof | |
| JP2008540602A (en) | Adsorbent colon delivery | |
| Farzaneh et al. | Molecularly imprinted polymer nanoparticles for olanzapine recognition: application for solid phase extraction and sustained release | |
| Seifi et al. | Preparation and study of tramadol imprinted micro-and nanoparticles by precipitation polymerization: Microwave irradiation and conventional heating method | |
| Zhang et al. | Sustained release of ibuprofen from polymeric micelles with a high loading capacity of ibuprofen in media simulating gastrointestinal tract fluids | |
| WO2010040086A1 (en) | Administration of an adsorbent polymer for treatment of systemic inflammation | |
| CN115449009B (en) | Cholesterol molecularly imprinted polymer and preparation method and application thereof | |
| Soleimani et al. | Photodegradable poly (ester amide) s for indirect light-triggered release of paclitaxel | |
| Viveiros et al. | Development of affinity polymeric particles for the removal of 4-dimethylaminopyridine (DMAP) from active pharmaceutical ingredient crude streams using a green technology | |
| CN1296053C (en) | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by body | |
| CN113426423B (en) | Adsorbent for removing LDL (low density lipoprotein) by extracorporeal blood circulation, preparation method thereof and perfusion device | |
| CN111704693B (en) | Pseudo template molecularly imprinted polymer and application thereof | |
| CN109908396A (en) | A kind of calcium ion-exchanged porous-starch hemostatic material and its preparation method and application | |
| CN115770224B (en) | Acrylic acid microsphere carrying paclitaxel medicine and preparation method thereof | |
| Ren et al. | Synthesis of high selectivity polymeric adsorbent and its application on the separation of ginkgo flavonol glycosides and terpene lactones | |
| JP2004131406A (en) | Uremic substance specifically recognizing polymer and oral adsorbent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |